Cronos Group (CRON) Competitors

Cronos Group (NASDAQ:CRON) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends.

Do insiders and institutionals hold more shares of CRON or VRNA?

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 6.9% of Cronos Group shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has better valuation & earnings, CRON or VRNA?

Verona Pharma has lower revenue, but higher earnings than Cronos Group. Verona Pharma is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$87.24M	8.94	-$73.96M	-$0.13	-15.69
Verona Pharma	$460K	6,779.26	-$54.37M	-$1.92	-20.32

Which has more volatility & risk, CRON or VRNA?

Cronos Group has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Does the MarketBeat Community believe in CRON or VRNA?

Cronos Group received 141 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 80.55% of users gave Verona Pharma an outperform vote while only 61.13% of users gave Cronos Group an outperform vote.

Company	Underperform	Outperform
Cronos Group	Outperform Votes 464 61.13%	Underperform Votes 295 38.87%
Verona Pharma	Outperform Votes 323 80.55%	Underperform Votes 78 19.45%

Is CRON or VRNA more profitable?

Verona Pharma has a net margin of 0.00% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -2.56% beat Verona Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-42.65%	-2.56%	-2.47%
Verona Pharma	N/A	-79.54%	-43.49%

Do analysts recommend CRON or VRNA?

Cronos Group presently has a consensus price target of $3.00, indicating a potential upside of 47.06%. Verona Pharma has a consensus price target of $43.83, indicating a potential upside of 12.36%. Given Cronos Group's higher probable upside, equities research analysts clearly believe Cronos Group is more favorable than Verona Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verona Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer CRON or VRNA?

In the previous week, Cronos Group had 4 more articles in the media than Verona Pharma. MarketBeat recorded 10 mentions for Cronos Group and 6 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 1.30 beat Cronos Group's score of 0.18 indicating that Verona Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verona Pharma	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cronos Group beats Verona Pharma on 10 of the 18 factors compared between the two stocks.